search
Back to results

Study of the Neurobiology of Tourette Syndrome and Related Disorders

Primary Purpose

Tourette Syndrome, Obsessive Compulsive Disorder

Status
Completed
Phase
Locations
United States
Study Type
Observational
Intervention
Sponsored by
National Center for Research Resources (NCRR)
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an observational trial for Tourette Syndrome focused on measuring Tourette syndrome, anxiety disorder, disease-related problem/condition, neurologic and psychiatric disorders, obsessive compulsive disorder, oncologic disorders, rare disease

Eligibility Criteria

12 Years - 45 Years (Child, Adult)All SexesDoes not accept healthy volunteers

PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Diagnostic and Statistical Manual of Mental Disorders IV lifetime diagnosis of 1 or more of the following: Tourette syndrome (TS) Obsessive compulsive disorder Chronic tics Severely affected adolescents with a score of 3 or greater on the TS-Clinical Global Impression Scale eligible --Prior/Concurrent Therapy-- At least 1 month since any medication --Patient Characteristics-- Other: In good physical health No alcohol or substance abuse No Intelligence Quotient below 80 Negative pregnancy test required of fertile women

Sites / Locations

  • Yale University School of Medicine

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
October 18, 1999
Last Updated
June 23, 2005
Sponsor
National Center for Research Resources (NCRR)
Collaborators
Yale University
search

1. Study Identification

Unique Protocol Identification Number
NCT00004325
Brief Title
Study of the Neurobiology of Tourette Syndrome and Related Disorders
Study Type
Observational

2. Study Status

Record Verification Date
January 2004
Overall Recruitment Status
Completed
Study Start Date
December 1988 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
National Center for Research Resources (NCRR)
Collaborators
Yale University

4. Oversight

5. Study Description

Brief Summary
OBJECTIVES: I. Investigate the pathobiology of Tourette syndrome and related disorders by measuring various compounds of interest in cerebrospinal fluid, plasma, and urine of patients with Tourette syndrome, obsessive compulsive disorder, and/or chronic tics. II. Determine the pattern of familial aggregation of Tourette syndrome and obsessive compulsive disorder by systematic assessment of all first-degree family members of patients selected for cerebrospinal fluid studies. III. Establish the neurochemical and neuropeptide profile associated with the range of expression of the putative Tourette gene expression in adult and adolescent patients.
Detailed Description
PROTOCOL OUTLINE: All patients are screened with a complete physical and neurologic exam, and a semi-structured interview. Patients then receive a comprehensive assessment of systemic disease. Patients and first-degree family members also participate in a genetic study. Any patient who experiences an unusual exacerbation of symptoms or significant side effects is removed from the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tourette Syndrome, Obsessive Compulsive Disorder
Keywords
Tourette syndrome, anxiety disorder, disease-related problem/condition, neurologic and psychiatric disorders, obsessive compulsive disorder, oncologic disorders, rare disease

7. Study Design

Enrollment
200 (false)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Diagnostic and Statistical Manual of Mental Disorders IV lifetime diagnosis of 1 or more of the following: Tourette syndrome (TS) Obsessive compulsive disorder Chronic tics Severely affected adolescents with a score of 3 or greater on the TS-Clinical Global Impression Scale eligible --Prior/Concurrent Therapy-- At least 1 month since any medication --Patient Characteristics-- Other: In good physical health No alcohol or substance abuse No Intelligence Quotient below 80 Negative pregnancy test required of fertile women
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James F. Leckman
Organizational Affiliation
Yale University
Official's Role
Study Chair
Facility Information:
Facility Name
Yale University School of Medicine
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520-8035
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
10356639
Citation
van Wattum PJ, Anderson GM, Chappell PB, Goodman WK, Riddle MA, Leckman JF. Cerebrospinal fluid dynorphin A[1-8] and beta-endorphin levels in Tourette's syndrome are unaltered. Biol Psychiatry. 1999 Jun 1;45(11):1527-8. doi: 10.1016/s0006-3223(98)00313-8. No abstract available. Erratum In: Biol Psychiatry 1999 Nov 15;46(10):following 1444.
Results Reference
background
PubMed Identifier
9861477
Citation
Peterson BS, Leckman JF. The temporal dynamics of tics in Gilles de la Tourette syndrome. Biol Psychiatry. 1998 Dec 15;44(12):1337-48. doi: 10.1016/s0006-3223(98)00176-0.
Results Reference
background
PubMed Identifier
9298805
Citation
Cohen DJ, Leckman JF, Pauls D. Neuropsychiatric disorders of childhood: Tourette's syndrome as a model. Acta Paediatr Suppl. 1997 Jul;422:106-11. doi: 10.1111/j.1651-2227.1997.tb18357.x.
Results Reference
background
PubMed Identifier
8988803
Citation
Rasmusson AM, Anderson GM, Lynch KA, McSwiggan-Hardin M, Scahill LD, Mazure CM, Goodman WK, Price LH, Cohen DJ, Leckman JF. A preliminary study of tryptophan depletion on tics, obsessive-compulsive symptoms, and mood in Tourette's syndrome. Biol Psychiatry. 1997 Jan 1;41(1):117-21. doi: 10.1016/s0006-3223(96)00380-0. No abstract available.
Results Reference
background
PubMed Identifier
8195454
Citation
Peterson BS, Leckman JF, Scahill L, Naftolin F, Keefe D, Charest NJ, King RA, Hardin MT, Cohen DJ. Steroid hormones and Tourette's syndrome: early experience with antiandrogen therapy. J Clin Psychopharmacol. 1994 Apr;14(2):131-5.
Results Reference
background
PubMed Identifier
8731518
Citation
Chappell P, Leckman J, Goodman W, Bissette G, Pauls D, Anderson G, Riddle M, Scahill L, McDougle C, Cohen D. Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls. Biol Psychiatry. 1996 May 1;39(9):776-83. doi: 10.1016/0006-3223(95)00221-9.
Results Reference
background
PubMed Identifier
8080901
Citation
Chappell P, Riddle M, Anderson G, Scahill L, Hardin M, Walker D, Cohen D, Leckman J. Enhanced stress responsivity of Tourette syndrome patients undergoing lumbar puncture. Biol Psychiatry. 1994 Jul 1;36(1):35-43. doi: 10.1016/0006-3223(94)90060-4.
Results Reference
background
PubMed Identifier
9861478
Citation
Martin A, State M, Anderson GM, Kaye WM, Hanchett JM, McConaha CW, North WG, Leckman JF. Cerebrospinal fluid levels of oxytocin in Prader-Willi syndrome: a preliminary report. Biol Psychiatry. 1998 Dec 15;44(12):1349-52. doi: 10.1016/s0006-3223(98)00190-5.
Results Reference
background
PubMed Identifier
7766289
Citation
Leckman JF, Goodman WK, Anderson GM, Riddle MA, Chappell PB, McSwiggan-Hardin MT, McDougle CJ, Scahill LD, Ort SI, Pauls DL, et al. Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology. 1995 Feb;12(1):73-86. doi: 10.1038/sj.npp.1380241.
Results Reference
background
PubMed Identifier
2742727
Citation
Riddle MA, Jatlow PI, Anderson GM, Cho SC, Hardin MT, Cohen DJ, Leckman JF. Plasma debrisoquin levels in the assessment of reduction of plasma homovanillic acid. The debrisoquin method. Neuropsychopharmacology. 1989 Jun;2(2):123-9. doi: 10.1016/0893-133x(89)90015-8.
Results Reference
background
PubMed Identifier
2304369
Citation
Anderson GM, Mefford IN, Tolliver TJ, Riddle MA, Ocame DM, Leckman JF, Cohen DJ. Serotonin in human lumbar cerebrospinal fluid: a reassessment. Life Sci. 1990;46(4):247-55. doi: 10.1016/0024-3205(90)90030-u.
Results Reference
background
PubMed Identifier
1699245
Citation
Leckman JF, Goodman WK, Riddle MA, Hardin MT, Anderson GM. Low CSF 5HIAA and obsessions of violence: report of two cases. Psychiatry Res. 1990 Jul;33(1):95-9. doi: 10.1016/0165-1781(90)90152-u. No abstract available.
Results Reference
background
PubMed Identifier
2209489
Citation
Leckman JF, Chittenden EH. Gilles de La Tourette's syndrome and some forms of obsessive-compulsive disorder may share a common genetic diathesis. Encephale. 1990 Jul-Aug;16 Spec No:321-3.
Results Reference
background
PubMed Identifier
6155891
Citation
Leckman JF, Cohen DJ, Shaywitz BA, Caparulo BK, Heninger GR, Bowers MB Jr. CSF monoamine metabolites in child and adult psychiatric patients. A developmental perspective. Arch Gen Psychiatry. 1980 Jun;37(6):677-81. doi: 10.1001/archpsyc.1980.01780190075009.
Results Reference
background
PubMed Identifier
6161049
Citation
Shaywitz BA, Cohen DJ, Leckman JF, Young JG, Bowers MB Jr. Ontogeny of dopamine and serotonin metabolites in the cerebrospinal fluid of children with neurological disorders. Dev Med Child Neurol. 1980 Dec;22(6):748-54. doi: 10.1111/j.1469-8749.1980.tb03741.x.
Results Reference
background
PubMed Identifier
6180470
Citation
Young JG, Cohen DJ, Shaywitz SE, Caparulo BK, Kavanagh ME, Hunt RD, Leckman JF, Anderson GM, Detlor J, Harcherik D, Shaywitz BA. Assessment of brain function in clinical pediatric research: behavioral and biological strategies. Schizophr Bull. 1982;8(2):205-35. doi: 10.1093/schbul/8.2.205.
Results Reference
background
PubMed Identifier
6279049
Citation
Sternberg DE, Charney DS, Heninger GR, Leckman JF, Hafstad KM, Landis DH. Impaired presynaptic regulation of norepinephrine in schizophrenia. Effects of clonidine in schizophrenic patients and normal controls. Arch Gen Psychiatry. 1982 Mar;39(3):285-9. doi: 10.1001/archpsyc.1982.04290030025004.
Results Reference
background
PubMed Identifier
6324164
Citation
Leckman JF, Cohen DJ. Recent advances in Gilles de la Tourette syndrome: implications for clinical practice and future research. Psychiatr Dev. 1983 Autumn;1(3):301-16.
Results Reference
background
PubMed Identifier
2854734
Citation
Rimar S, Shaywitz SE, Shaywitz BA, Lister G, Anderson GM, Leckman JF, Cohen DJ. Autonomic dysfunction, peripheral neuropathy, and depression. Pediatr Neurol. 1985 Mar-Apr;1(2):120-3. doi: 10.1016/0887-8994(85)90049-9.
Results Reference
background
PubMed Identifier
9232461
Citation
Leckman JF, Peterson BS, Anderson GM, Arnsten AF, Pauls DL, Cohen DJ. Pathogenesis of Tourette's syndrome. J Child Psychol Psychiatry. 1997 Jan;38(1):119-42. doi: 10.1111/j.1469-7610.1997.tb01508.x.
Results Reference
background
PubMed Identifier
2463450
Citation
Leckman JF, Riddle MA, Berrettini WH, Anderson GM, Hardin M, Chappell P, Bissette G, Nemeroff CB, Goodman WK, Cohen DJ. Elevated CSF dynorphin A [1-8] in Tourette's syndrome. Life Sci. 1988;43(24):2015-23. doi: 10.1016/0024-3205(88)90575-9.
Results Reference
background
PubMed Identifier
6163366
Citation
Leckman JF, Bowers MB Jr, Sturges JS. Relationship between estimated premorbid adjustment and CSF homovanillic acid and 5-hydroxyindoleacetic acid levels. Am J Psychiatry. 1981 Apr;138(4):472-7. doi: 10.1176/ajp.138.4.472.
Results Reference
background

Learn more about this trial

Study of the Neurobiology of Tourette Syndrome and Related Disorders

We'll reach out to this number within 24 hrs